University Hospitals Birmingham NHS Foundation Trust

Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Retrieved on: 
Friday, November 3, 2023
PD-L1, United Kingdom, NSCLC, Medication, Mirati, Lung cancer, University Hospital (Newark, New Jersey), University Hospitals Birmingham NHS Foundation Trust, MHRA, Immunotherapy, Medicines and Healthcare products Regulatory Agency, Therapy, Patient, Mirati Therapeutics, SAN, Pharmaceutical industry

"KRAZATI offers a compelling therapeutic option for patients with previously treated locally advanced NSCLC with a KRASG12C mutation.

Key Points: 
  • "KRAZATI offers a compelling therapeutic option for patients with previously treated locally advanced NSCLC with a KRASG12C mutation.
  • "Fourteen percent of people living with NSCLC harbour the KRASG12C mutation yet there are limited targeted treatment options for patients with this devastating disease1,2," said Dr Shobhit Baijal (Consultant Medical Oncologist of The University Hospital Birmingham).
  • "The expansion of treatment options for NSCLC benefits patients and clinicians alike.
  • As someone intensively involved in the management of lung cancer patients, I look forward to KRAZATI being available for use in clinical practice."

The UK Regulatory Agency (MHRA) Approved the Protocol of LIBERATE Study, the First Clinical Trial Evaluating Glenzocimab for Heart Attacks

Retrieved on: 
Thursday, September 7, 2023
Health, Other Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Percutaneous coronary intervention, Northern General Hospital, Queen Elizabeth Hospital Birmingham (1933–2010), Partnership, University, Therapy, Myocardial infarction, BHP, Clinical trial, Splenic infarction, Sri Jayadeva Institute of Cardiovascular Sciences and Research, STEMI, Associate, Trial of the century, Journal, Patient, University of Birmingham, University Hospitals Birmingham NHS Foundation Trust, Journal of Thrombosis and Haemostasis, Thrombosis, Hospital, Queen Elizabeth Hospital, Safety, Pharmaceutical industry

September 7th, 2023, the University of Birmingham and Acticor Biotech (Paris:ALACT) announce the full regulatory approval of LIBERATE clinical study.

Key Points: 
  • September 7th, 2023, the University of Birmingham and Acticor Biotech (Paris:ALACT) announce the full regulatory approval of LIBERATE clinical study.
  • In 2021, the University of Birmingham and Acticor Biotech signed a partnership agreement to evaluate glenzocimab efficacy in myocardial infarction in a new clinical trial called LIBERATE.
  • This new clinical trial is based on a long-standing collaboration between Acticor Biotech and the University of Birmingham.
  • We are very pleased to receive regulatory approval to launch the LIBERATE clinical trial to investigate whether glenzocimab can reduce the type of blood clotting that causes heart damage during heart attacks.

World-Leading Real World Data Registry, TARGET-NASH, Surpasses 7,000+ Enrolled Patients and 500,000+ Months of Patient Follow-Up

Retrieved on: 
Wednesday, June 21, 2023
Hepatocellular carcinoma, Doctor of Philosophy, AASLD, University of Birmingham, Congress, Incidence, Plasma, Patient, Hepatology, Risk, University Hospitals Birmingham NHS Foundation Trust, NAFLD, HCC, Disease, University, Therapy, NASH, Liver disease, HIV disease progression rates, Data, Oklahoma Office of the Chief Medical Examiner, Fatty liver disease, Entrepreneurship, Immunology, FDA, Cirrhosis, DAA, Biomarker, National Institute for Health and Care Research, Fibrosis, Clutch (eggs), Mortality, EASL, Partnership, American Association for Cancer Research, NIHR, RWE, Recurrence, HCV, Nursing, Pharmaceutical industry, Vaccine, MD, Immunotherapy

DURHAM, N.C., June 21, 2023 /PRNewswire/ -- Real world evidence (RWE) leader, Target RWE, today shared updates from its nonalcoholic steatohepatitis (NASH) longitudinal registry of more than 7,000 enrolled patients, representing more than 500,000 patient months of follow up, making TARGET-NASH the most mature dataset following patients with nonalcoholic fatty liver disease (NAFLD) and NASH in the world. Target RWE will be presenting new data from its TARGET-NASH and TARGET-HCC cohorts at the annual EASL Congress in Vienna, Austria June 21-24th, including disease progression and results from a post-authorization safety study.

Key Points: 
  • Estimating fibrosis progression in patients with NAFLD/NASH is essential for understanding the comprehensive burden of disease, risk of future liver-related morbidity and to inform future clinical trial designs.
  • Progression outcomes included all-cause mortality, progression from non-cirrhosis to cirrhosis and from compensated to decompensated cirrhosis, and liver-related and cardiovascular events.
  • "Identifying patient profiles in the real world who may benefit from these novel treatments will be critical.
  • Real world evidence from the TARGET-NASH cohort has been presented and published in numerous peer-reviewed journals and major academic conferences.

The Evolution and Impact of ePROs in Clinical Trials, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, April 17, 2023
Shadow King, University, University Hospitals Birmingham NHS Foundation Trust, Patient, University of Birmingham, TLC, Long, Pharmaceutical industry, Nursing

TORONTO, April 17, 2023 /PRNewswire-PRWeb/ -- This webinar will examine the importance of electronic patient-reported outcomes (ePROs) and how working at pace with methodological rigour led to the development of the Symptom Burden Questionnaire™ (SBQ™), a new ePRO measure which includes 16 symptoms scales, each measuring a different symptom. The featured speakers will also talk about the feasibility trial of non-pharmacological interventions as part of the Therapies for Long COVID (TLC) study.

Key Points: 
  • In this free webinar, learn about the impact of electronic patient-reported outcomes (ePROs) through a unique ePRO measure that is tailored to individual patient needs.
  • Attendees will learn about the evolution of ePROs based on the work at University of Birmingham's Centre for Patient Reported Outcome Research.
  • To avoid increasing health disparities in clinical trials, underserved groups should be included through PRO-specific ethical guidelines for clinical research so that patient-reported outcomes are collected.
  • Register for this webinar to learn about the impact of ePROs through a unique ePRO measure that is tailored to individual patient needs.

Ibex Scoops Second Win of The UK Artificial Intelligence Award with Leading NHS Trusts

Retrieved on: 
Monday, March 6, 2023
North West Anglia NHS Foundation Trust, Social work, Trust, Hospital, Prostate cancer, University Hospitals Cleveland Medical Center, Diagnosis, Betsi Cadwaladr University Health Board, University of Nottingham, University, Artificial intelligence, TEL, Imperial College London, Deep learning, Nottingham University Hospitals NHS Trust, Patient, Cambridge University Hospitals NHS Foundation Trust, Cancer, NHS foundation trust, National Health Service, University Hospitals Coventry and Warwickshire NHS Trust, University Hospitals Birmingham NHS Foundation Trust, Breast cancer, Government, Pathology, Oxford University Press, Entrepreneurship, UK Health Security Agency, Doctor of Philosophy, Marie Cassidy, Nursing, University College London, NIHR, NHS, Pharmaceutical industry, Medical imaging, Ibex, Health, AI, Nature

TEL AVIV, Israel, March 6, 2023 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, University of Nottingham and a consortium of NHS Trusts, announced today they are winners of the UK Artificial Intelligence in Health and Care Award, enabling the deployment of Ibex's Galen™ Breast solution across five National Health Services (NHS) and delivering on their aligned missions of improving breast cancer diagnosis and lab efficiency.

Key Points: 
  • Galen Breast supports pathologists by providing AI-based tools and insights that help detect and grade different types of breast cancer.
  • The solution will be deployed at Nottingham University Hospitals, Cambridge University Hospitals, North West Anglia NHS Foundation Trust, Betsi Cadwaladr University Health Board and University Hospitals Birmingham.
  • Timely and accurate diagnosis can significantly impact breast cancer survival rates, making Ibex's solution a vital and welcome addition into NHS trusts."
  • "We are proud to receive this award from the NIHR and NHS, said Chaim Linhart, PhD, Co-Founder and Chief Technology Officer of Ibex Medical Analytics.

Hardman & Co Research on Advanced Oncotherapy (AVO): Understanding the significance of 230MeV

Retrieved on: 
Thursday, February 2, 2023
CERN, NHS foundation trust, AVO, UHB, University Hospitals Birmingham NHS Foundation Trust, Medical imaging

Hardman & Co Research on Advanced Oncotherapy:

Key Points: 
  • Hardman & Co Research on Advanced Oncotherapy:
    AVO’s goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology, developed originally at the world-renowned CERN.
  • The complex assembly of the first LIGHT accelerator in Daresbury (UK) has been completed and demonstrated to generate a full-energy proton beam (230MeV) required to treat deep-seated tumours.
  • AVO is now liaising with its clinical partner, University Hospitals Birmingham (UHB) NHS Foundation Trust, to prepare for first-patient treatments in 2H’23.
  • Following this significant project de-risking, our updated LIGHT model shows that AVO could become EBITDA-positive in 2025.

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Retrieved on: 
Monday, January 9, 2023
Biotechnology, Pharmaceutical, Health, Cardiology, University, Hospital, IRB, Alteplase, AP, Type, University Hospitals Birmingham NHS Foundation Trust, Agence nationale de sécurité du médicament et des produits de santé, Partnership, Marketing, Assistance Publique–Hôpitaux de Paris, Stroke, Infarction, ISIN, RHU, Biologics license application, European Medicines Agency, Death, Quality of life, Pulmonary embolism, BLA, EVT, Sri Jayadeva Institute of Cardiovascular Sciences and Research, TNK, EMA, Agence nationale de la recherche, FDA, MRS, Disability, Tenecteplase, IRAS, Șaeș, Reperfusion, Standard of care, Safety, IPO, Modified Rankin Scale, Patient, Thrombectomy, Myocardial infarction, GREEN, Pharmaceutical industry, Medical imaging

ACTICOR BIOTECH (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, today provides an update on the progress of its clinical programs with glenzocimab, its lead drug candidate.

Key Points: 
  • ACTICOR BIOTECH (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, today provides an update on the progress of its clinical programs with glenzocimab, its lead drug candidate.
  • We have fully met our patient enrollment goals in 2022 and are involving new countries and hospitals in 2023.
  • We look forward to continuing the clinical development of glenzocimab in the treatment of myocardial infarction in partnership with the University of Birmingham (UK).
  • The recognition of this pivotal study design supports a future application for marketing authorization for glenzocimab in stroke in Europe.

Acticor Biotech: World’s First Clinical Trial to Test New Drug Glenzocimab for Heart Attacks

Retrieved on: 
Tuesday, November 22, 2022
Health, Research, Pharmaceutical, Science, Cardiology, Biotechnology, Newton, Clinical trial, CTU, Brain, Survival, University, Centre de documentation de la musique contemporaine, European Medicines Agency, Infarction, STEMI, University Hospitals Birmingham NHS Foundation Trust, Stroke, A&B, BHP, Blood, Medicine, ISIN, Queen Elizabeth Hospital, Degenerative disease, Partnership, Myocardial infarction, ESOC, Mortality, Intracerebral hemorrhage, Clinical trials unit, MI, University of Birmingham, EMA, Document, Angioplasty, Queen Elizabeth Hospital Birmingham (1933–2010), Thrombosis, GPVI, Therapy, Mab, Hospital, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Northern General Hospital, VI, Associate, Heart, Patient, Medical device, Pharmaceutical industry, INSERM, Cardiology

Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug for the first time.

Key Points: 
  • Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug for the first time.
  • A potential new drug to improve the long-term outcomes for heart attack patients will be trialled in the UK.
  • Although immediate opening of the blocked coronary artery by angioplasty in cases of heart attack is now routine, significant heart damage still occurs.
  • Were delighted to work with Acticor to see whether this new class of drug has the potential to improve the outcomes of our patients with heart attacks.

Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T-Cell Therapy Engager ALETA-001

Retrieved on: 
Monday, November 7, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Lymphoma, Ovarian cancer, BCMA, CD20, Edinburgh Cancer Research Centre, Queen Elizabeth Hospital, National Institute for Health and Care Excellence, Brain, Patient, NHL, Wales, Cancer, National Institute, Health care, Cancer Research UK, Innovation, ALL, Lymphoid leukemia, University Hospitals Birmingham NHS Foundation Trust, CAR, Entrepreneurship, CD19, Temozolomide, Healthcare Improvement Scotland, Neoplasm, Prostate cancer, SMC, CTE, Acute lymphoblastic leukemia, Lymphatic system, Antigen, NICE, Drug development, Medicine, Leukemia, Cancer research, MHRA, Therapy, The Queen Elizabeth Hospital, Adelaide, AML, B-cell maturation antigen, Pharmaceutical industry, Vaccine

Aleta Biotherapeutics (Aleta), a privately held immuno-oncology company with novel biologic CAR T engagers that work in synergy with cell therapies to improve outcomes for patients, announces that the U.K.

Key Points: 
  • Aleta Biotherapeutics (Aleta), a privately held immuno-oncology company with novel biologic CAR T engagers that work in synergy with cell therapies to improve outcomes for patients, announces that the U.K.
  • This designation for our biologic CAR T-cell therapy engager ALETA-001 marks an important step in addressing the high unmet need for patients who relapse or progress following CD19-targeted CAR T-cell therapy for blood cancers, such as lymphoma and leukemia, stated Paul Rennert, Co-Founder, Acting Chief Executive Officer and Chief Scientific Officer, Aleta Biotherapeutics.
  • ALETA-001 is an off-the-shelf preclinical biologic program developed to treat and prevent cell therapy relapse of existing CD19-targeted CAR T-cell therapies, termed CAR19 T cells.
  • Aleta Biotherapeutics is an immune-oncology company with a portfolio and platform of novel off-the-shelf biologic CAR T engagers (CTEs) that work in synergy with cell therapies to improve outcomes for patients.

Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022

Retrieved on: 
Monday, October 24, 2022
MBBS, Osteogenesis imperfecta, Therapy, Webcast, Daylight saving time, Alpha-1 antitrypsin deficiency, University Hospital (Newark, New Jersey), NASDAQ, Patient, Degenerative disease, University Hospitals Birmingham NHS Foundation Trust, R, BOS, Company, Q&A, Respiratory tract, GLOBE, OI, FDA, AATD, Pharmaceutical industry, Medicine

LONDON, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (Mereo or the Company), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that it will host a R&D update call on Monday, October 31, 2022 at 8:00 am ET on the alvelestat (MPH966) program for alpha-1-antitrypsin deficiency (AATD).

Key Points: 
  • LONDON, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (Mereo or the Company), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that it will host a R&D update call on Monday, October 31, 2022 at 8:00 am ET on the alvelestat (MPH966) program for alpha-1-antitrypsin deficiency (AATD).
  • The update will include commentary from and Q&A with leading pulmonary experts, further to the receipt of Fast Track Designation for alvelestat from the FDA announced on October 17, 2022.
  • The partnership with Ultragenyx includes potential milestone payments of up to $254 million and royalties to Mereo on Ultragenyx territories.
  • Mereo has retained EU and UK commercial rights and will pay Ultragenyx royalties on those territories.